Skip to main content

Table 2 Subgroup analysis by defining HER2 status by Hoffman validation criteria

From: The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature

Not fit Hoffman criteria Fit Hoffman criteria
Clinicopathological parameters Number of studies OR/RR(95% CI) P Heterogeneity Number of studies OR/RR(95%CI) P Heterogeneity
     I 2 (%) P value     I 2 (%) P value
Sex 18 1.34(1.15, 1.56) <0.001 0.0 0.716 15 1.63(1.41, 1.89) <0.001 42.4 0.042
Age 13 1.01(0.72, 1.41) 0.976 72.0 0.000 14 0.78(0.62, 0.99) 0.038 45.6 0.032
Tumor size 7 0.94(0.70, 1.26) 0.692 0.0 0.486 4 0.55(0.32, 0.96) 0.070 12.6 0.330
Tumor site 10 1.06(0.83, 1.37) 0.632 25.3 0.211 14 1.40(1.14, 1.71) 0.001 25.2 0.182
Lauren’s classification 17 3.67(2.47, 5.47) <0.001 76.2 <0.001 13 3.03(1.95,4.70) <0.001 73.4 <0.001
Differentiation grade 16 1.24(0.76, 2.05) 0.390 74.8 <0.001 12 2.71(1.66, 4.44) <0.001 76.8 <0.001
TNM stage (III+IV vs I+II) 14 1.53(1.05,2.23) 0.026 77.4 <0.001 10 1.23(1.04,1.46) 0.014 0.0 0.939
Lymph node metastasis 13 1.15(1.00, 1.33) 0.057 0.0 0.500 14 1.40(1.19, 1.64) <0.001 0.0 0.847
Distant metastasis 5 2.58(1.00, 6.67) 0.050 64.8 0.023 4 1.52(1.18, 1.95) 0.001 0.0 0.617
Lymphovascular invasion 6 1.18(0.75, 1.85) 0.468 74.1 0.002 4 2.16(0.87, 5.35) 0.096 0.0 0.421
Overall survival 4 1.95(1.38, 2.51) <0.001 0.0 0.583 6 1.11(0.68, 1.53) <0.001 70.8 0.004
  1. OR odds ratio, CI confidence interval, TNM tumor, node, metastasis